44 Chapter 2 60. Law WS, Genin JC, Miess C, Treton G, Warren AP, Lloyd P, Dudal S, Krantz C. Use of generic LC-MS/MS assays to characterize atypical PK profile of a biotherapeutic monoclonal antibody. Bioanalysis. 2014; 6: 3225-3235. 61. Gong C, Zheng N, Zeng J, Aubry AF, Arnold ME. Post-pellet-digestion precipitation and solid phase extraction: A practical and efficient workflow to extract surrogate peptides for ultra-high performance liquid chromatography--tandem mass spectrometry bioanalysis of a therapeutic antibody in the low ng/mL range. J Chromatogr A. 2015; 1424: 27-36. 62. Kaur S, Liu L, Cortes DF, Shao J, Jenkins R, Mylott WR, Jr., Xu K. Validation of a biotherapeutic immunoaffinity-LC-MS/MS assay in monkey serum: ‘plug-and-play’ across seven molecules. Bioanalysis. 2016; 8: 1565-1577. 63. Osaki F, Tabata K, Oe T. Quantitative LC/ESI-SRM/MS of antibody biopharmaceuticals: use of a homologous antibody as an internal standard and three-step method development. Anal Bioanal Chem. 2017; 409: 5523-5532. 64. Ouyang Z, Furlong MT, Wu S, Sleczka B, Tamura J, Wang H, Suchard S, Suri A, Olah T, Tymiak A, Jemal M. Pellet digestion: a simple and efficient sample preparation technique for LC-MS/MS quantification of large therapeutic proteins in plasma. Bioanalysis. 2012; 4: 17-28. 65. Fernandez Ocana M, James IT, Kabir M, Grace C, Yuan G, Martin SW, Neubert H. Clinical pharmacokinetic assessment of an anti-MAdCAM monoclonal antibody therapeutic by LC-MS/MS. Anal Chem. 2012; 84: 5959-5967. 66. Willrich MA, Murray DL, Barnidge DR, Ladwig PM, Snyder MR. Quantitation of infliximab using clonotypic peptides and selective reaction monitoring by LC-MS/MS. Int Immunopharmacol. 2015; 28: 513-520. 67. Bults P, Bischoff R, Bakker H, Gietema JA, van de Merbel NC. LC-MS/MS-Based Monitoring of In Vivo Protein Biotransformation: Quantitative Determination of Trastuzumab and Its Deamidation Products in Human Plasma. Anal Chem. 2016; 88: 1871-1877. 68. Iwamoto N, Shimada T, Terakado H, Hamada A. Validated LC-MS/MS analysis of immune checkpoint inhibitor Nivolumab in human plasma using a Fab peptide-selective quantitation method: nano-surface and molecular-orientation limited (nSMOL) proteolysis. J Chromatogr B Analyt Technol Biomed Life Sci. 2016; 1023-1024: 9-16. 69. Iwamoto N, Shimomura A, Tamura K, Hamada A, Shimada T. LC-MS bioanalysis of Trastuzumab and released emtansine using nano-surface and molecular-orientation limited (nSMOL) proteolysis and liquid-liquid partition in plasma of Trastuzumab emtansine-treated breast cancer patients. J Pharm Biomed Anal. 2017; 145: 33-39. 70. Iwamoto N, Takanashi M, Hamada A, Shimada T. Validated LC/MS Bioanalysis of Rituximab CDR Peptides Using Nano-surface and Molecular-Orientation Limited (nSMOL) Proteolysis. Biol Pharm Bull. 2016; 39: 1187-1194. 71. Iwamoto N, Umino Y, Aoki C, Yamane N, Hamada A, Shimada T. Fully validated LCMS bioanalysis of Bevacizumab in human plasma using nano-surface and molecular-orientation limited (nSMOL) proteolysis. Drug Metab Pharmacokinet. 2016; 31: 46-50. 72. El Amrani M, van den Broek MP, Gobel C, van Maarseveen EM. Quantification of active infliximab in human serum with liquid chromatography-tandem mass spectrometry using a tumor necrosis factor alpha -based pre-analytical sample purification and a stable isotopic labeled infliximab bio-similar as internal standard: A target-based, sensitive and cost-effective method. J Chromatogr A. 2016; 1454: 42-48.
RkJQdWJsaXNoZXIy MTk4NDMw